Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor- agonist, which is in Phase III clinical trials for the treatment of non-alcoholic steatohepatitis. The company also develops MGL-3745, a backup compound to resmetirom. It has research, development, and commercialization agreement with Hoffmann-La Roche. Madrigal Pharmaceuticals, Inc. is headquartered in West Conshohocken, Pennsylvania.

Madrigal Pharmaceuticals, Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

CONSHOHOCKEN, PA., MAY 07, 2026 (GLOBE NEWSWIRE) -- MADRIGAL PHARMACEUTICALS, INC. (NASDAQ:MDGL), A BIOPHARMACEUTICAL COMPANY FOCUSED ON DELIVERING NOVEL THERAPEUTICS FOR METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS (MASH), TODAY ANNOUNCED THAT IT GRANTED EQUITY AWARDS ON MAY 1, 2026 TO 47 NEW NON-EXECUTIVE EMPLOYEES AS EQUITY INDUCEMENT AWARDS UNDER THE TERMS OF MADRIGAL'S 2025 INDUCEMENT PLAN.

MADRIGAL PHARMACEUTICALS ANNOUNCES GRANTS OF INDUCEMENT AWARDS UNDER NASDAQ LISTING RULE 5635(C)(4)

CONSHOHOCKEN, PA., MAY 06, 2026 (GLOBE NEWSWIRE) -- MADRIGAL PHARMACEUTICALS, INC. (NASDAQ: MDGL), A BIOPHARMACEUTICAL COMPANY FOCUSED ON DELIVERING NOVEL THERAPEUTICS FOR METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS (MASH), TODAY REPORTS FIRST-QUARTER 2026 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATES.

MADRIGAL PHARMACEUTICALS REPORTS FIRST-QUARTER 2026 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATES

COMPANY ADVANCES ITS LEADERSHIP IN MASH WITH CLINICAL-STAGE, GENETICALLY TARGETED SIRNA ASSET FROM ARROWHEAD PHARMACEUTICALS PRECISION APPROACH TARGETS PATIENTS WHO HAVE A MUTATION IN THE PNPLA3 GENE, WHICH IS HIGHLY PREVALENT AMONG HISPANIC PATIENTS WITH MASH PHASE 1 DATA PUBLISHED IN THE NEW ENGLAND JOURNAL OF MEDICINE DEMONSTRATED A 46% LIVER FAT REDUCTION IN HOMOZYGOUS PATIENTS AND A WELL-TOLERATED SAFETY PROFILE MADRIGAL'S PIPELINE INCLUDES MORE THAN 10 PROGRAMS AT MULTIPLE STAGES OF DEVELOPMENT, ANCHORED BY REZDIFFRA  (RESMETIROM) AS THE FOUNDATIONAL TREATMENT CONSHOHOCKEN, PA., MAY 05, 2026 (GLOBE NEWSWIRE) -- MADRIGAL PHARMACEUTICALS, INC. (NASDAQ: MDGL), A BIOPHARMACEUTICAL COMPANY FOCUSED ON DELIVERING NOVEL THERAPEUTICS FOR METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS (MASH), TODAY ANNOUNCED AN EXCLUSIVE GLOBAL LICENSE AGREEMENT WITH ARROWHEAD PHARMACEUTICALS FOR ARO-PNPLA3, A CLINICAL-STAGE, SMALL INTERFERING RNA (SIRNA) ASSET TARGETING PATATIN-LIKE PHOSPHOLIPASE DOMAIN-CONTAINING PROTEIN 3 (PNPLA3), A KEY GENETIC DRIVER OF MASH.

MADRIGAL ADDS CLINICAL-STAGE SIRNA ASSET TARGETING PNPLA3 TO ITS MASH PIPELINE

PASADENA, CALIF.--(BUSINESS WIRE)---- $ARWR--ARROWHEAD PHARMACEUTICALS, INC. (NASDAQ: ARWR) TODAY ANNOUNCED AN EXCLUSIVE WORLDWIDE LICENSE AGREEMENT WITH MADRIGAL PHARMACEUTICALS (NASDAQ: MDGL) FOR ARO-PNPLA3, ARROWHEAD'S CLINICAL STAGE RNA INTERFERENCE (RNAI) THERAPEUTIC DESIGNED TO REDUCE LIVER EXPRESSION OF PATATIN-LIKE PHOSPHOLIPASE DOMAIN CONTAINING 3 (PNPLA3) AS A POTENTIAL TREATMENT FOR PATIENTS WITH METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS (MASH). THE EARLY CLINICAL DATA FOR ARO-PNPLA3 H.

ARROWHEAD PHARMACEUTICALS LICENSES CLINICAL MASH PROGRAM TARGETING PNPLA3 TO MADRIGAL PHARMACEUTICALS

CONSHOHOCKEN, PA., APRIL 22, 2026 (GLOBE NEWSWIRE) -- MADRIGAL PHARMACEUTICALS, INC. (NASDAQ: MDGL) ANNOUNCED TODAY THAT IT WILL RELEASE ITS FIRST-QUARTER 2026 FINANCIAL RESULTS ON WEDNESDAY, MAY 6, 2026, PRIOR TO THE OPEN OF THE U.S. FINANCIAL MARKETS.

MADRIGAL PHARMACEUTICALS TO RELEASE FIRST-QUARTER 2026 FINANCIAL RESULTS AND HOST WEBCAST ON MAY 6, 2026

CONSHOHOCKEN, PA., APRIL 21, 2026 (GLOBE NEWSWIRE) -- MADRIGAL PHARMACEUTICALS, INC. (NASDAQ:MDGL), A BIOPHARMACEUTICAL COMPANY FOCUSED ON DELIVERING NOVEL THERAPEUTICS FOR METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS (MASH), TODAY ANNOUNCED THAT IT GRANTED EQUITY AWARDS ON APRIL 1, 2026 TO 12 NEW NON-EXECUTIVE EMPLOYEES AS EQUITY INDUCEMENT AWARDS UNDER THE TERMS OF MADRIGAL'S 2025 INDUCEMENT PLAN. THE EQUITY AWARDS WERE APPROVED BY MADRIGAL'S INDEPENDENT COMPENSATION COMMITTEE IN ACCORDANCE WITH NASDAQ LISTING RULE 5635(C)(4).

CONSHOHOCKEN, PA., APRIL 07, 2026 (GLOBE NEWSWIRE) -- MADRIGAL PHARMACEUTICALS, INC. (NASDAQ:MDGL), A BIOPHARMACEUTICAL COMPANY FOCUSED ON DELIVERING NOVEL THERAPEUTICS FOR METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS (MASH), TODAY ANNOUNCED THAT IT GRANTED EQUITY AWARDS ON APRIL 1, 2026 TO 20 NEW NON-EXECUTIVE EMPLOYEES AS EQUITY INDUCEMENT AWARDS UNDER THE TERMS OF MADRIGAL'S 2025 INDUCEMENT PLAN.

CONSHOHOCKEN, PA., MARCH 19, 2026 (GLOBE NEWSWIRE) -- MADRIGAL PHARMACEUTICALS, INC. (NASDAQ:MDGL), A BIOPHARMACEUTICAL COMPANY FOCUSED ON DELIVERING NOVEL THERAPEUTICS FOR METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS (MASH), TODAY ANNOUNCED THAT IT GRANTED EQUITY AWARDS ON MARCH 15, 2026 TO SEVEN NEW NON-EXECUTIVE EMPLOYEES AS EQUITY INDUCEMENT AWARDS UNDER THE TERMS OF MADRIGAL'S 2025 INDUCEMENT PLAN. THE EQUITY AWARDS WERE APPROVED BY MADRIGAL'S INDEPENDENT COMPENSATION COMMITTEE IN ACCORDANCE WITH NASDAQ LISTING RULE 5635(C)(4).

CONSHOHOCKEN, PA., MARCH 05, 2026 (GLOBE NEWSWIRE) -- MADRIGAL PHARMACEUTICALS, INC. (NASDAQ:MDGL), A BIOPHARMACEUTICAL COMPANY FOCUSED ON DELIVERING NOVEL THERAPEUTICS FOR METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS (MASH), TODAY ANNOUNCED THAT IT GRANTED EQUITY AWARDS ON MARCH 1, 2026 TO 20 NEW NON-EXECUTIVE EMPLOYEES AS EQUITY INDUCEMENT AWARDS UNDER THE TERMS OF MADRIGAL'S 2025 INDUCEMENT PLAN. THE EQUITY AWARDS WERE APPROVED BY MADRIGAL'S INDEPENDENT COMPENSATION COMMITTEE IN ACCORDANCE WITH NASDAQ LISTING RULE 5635(C)(4).

CONSHOHOCKEN, PA., FEB. 24, 2026 (GLOBE NEWSWIRE) -- MADRIGAL PHARMACEUTICALS, INC. (NASDAQ: MDGL) TODAY ANNOUNCED THAT THE COMPANY WILL PARTICIPATE IN THE TD COWEN 46TH ANNUAL HEALTH CARE CONFERENCE ON TUESDAY, MARCH 3, 2026 AT 2:30 P.M.

Madrigal Pharmaceuticals, Inc.

MDGL

Price

Financial Reports

No items found.

Press Releases

Madrigal Pharmaceuticals, Inc.

MDGL.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financial Reports

No items found.

Press Releases

MDGL